Vergent Biosciences is a clinical stage biotech company developing innovative imaging probes and tracers for life science research, biopharma drug development and clinical diagnostics. Their focus today is on imaging probes that detect cell death (specifically apoptosis) in disease, with applications in screening, toxicology and efficacy studies.
Research applications: Their customers include academic, research institutes, biopharma anc CROs. Apoptosis is important to many areas of study, including embryonic development, mechanisms of disease, drug development and cell signaling. The imaging probes provide critical information during screening, toxicology and efficacy studies.
Clinical applications: Vergent endeavor to bring their caspase enzyme detection technology into clinics to detect and diagnose human disease, including early signs of pathogenesis/infection, chronic inflammatory processes and autoimmune diseases. Detecting caspase-mediated apoptosis will help healthcare professionals better address toxicity, tissue damage and therapeutic effectiveness.